九牧王(601566.SH):子公司擬認繳蘇州凱輝成長投資基金合夥企業出資額3000萬元
格隆匯 1 月 4日丨九牧王(601566.SH)公佈,公司的全資子公司西藏工布江達縣九盛投資有限責任公司(“九盛投資”)於2020年12月31日與凱輝成長(蘇州)商務諮詢有限公司(合夥企業的普通合夥人,“凱輝商務”)簽署了《蘇州凱輝成長投資基金合夥企業(有限合夥)有限合夥協議》(“合夥協議”),九盛投資作為新加入的有限合夥人擬認繳蘇州凱輝成長投資基金合夥企業(有限合夥)(“合夥企業”)出資額人民幣3000萬元。
此次投資旨在獲取財務投資收益,公司在保證日常經營所需資金的前提下,使用自有資金進行財務投資,有利於提高資金使用效率,且不會影響公司日常生產經營活動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.